866-997-4948(US-Canada Toll Free)

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Cancer

No. of Pages : 60 Pages


Global Markets Directs, \'Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
  • A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 14
Tekmira Pharmaceuticals Corp. 14
Pfizer Inc. 15
Insys Therapeutics, Inc. 16
Ascenta Therapeutics, Inc. 17
Orphagen Pharmaceuticals, Inc. 18
Atterocor, Inc. 19
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Assessment by Therapeutic Class 31
Drug Profiles 33
axitinib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AT-101 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
cintredekin besudotox - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TKM-PLK1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ATR-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Steroidogenic Factor-1 Antagonists - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates 48
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 54
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 55
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 56
Featured News & Press Releases 56
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 56
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 56
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 58

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table


Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2013 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Tekmira Pharmaceuticals Corp., H2 2013 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Pfizer Inc., H2 2013 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Insys Therapeutics, Inc., H2 2013 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Ascenta Therapeutics, Inc., H2 2013 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2013 18
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Atterocor, Inc., H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Number of Products by Stage and Target, H2 2013 23
Number of Products by Stage and Mechanism of Action, H2 2013 26
Number of Products by Stage and Route of Administration, H2 2013 28
Number of Products by Stage and Molecule Type, H2 2013 30
Number of Products by Stage and Therapeutic Class, H2 2013 32
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Recent Pipeline Updates, H2 2013 48
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2013 54
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2013 55

List of Chart


Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2013 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 11
Assessment by Monotherapy Products, H2 2013 20
Number of Products by Top 10 Target, H2 2013 21
Number of Products by Stage and Top 10 Target, H2 2013 22
Number of Products by Top 10 Mechanism of Action, H2 2013 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 25
Number of Products by Top 10 Route of Administration, H2 2013 27
Number of Products by Stage and Top 10 Route of Administration, H2 2013 28
Number of Products by Top 10 Molecule Type, H2 2013 29
Number of Products by Stage and Top 10 Molecule Type, H2 2013 30
Number of Products by Top 10 Therapeutic Class, H2 2013 31
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *